People · Operator
Named in public records as an officer, director or promoter · active 2018–2025 · Biotechnology, Other Health Care, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Kura Oncology, Inc. | — | Biotechnology | Series D+ | $241.7M | $1.9B | 2024 |
| TriSalus Life Sciences, Inc. | — | Other Health Care | Series C | $209.1M | $145.1M | 2024 |
| Zikani Therapeutics, Inc. | — | Pharmaceuticals | Series A | $31.7M | $232.3M | 2018 |
Mary Szela at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mary Szela on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| DIANE PARKS | 2 | 2 |
| Lawrence Miller | 1 | 8 |
| TROY WILSON | 1 | 7 |
| Joseph Zakrzewski | 1 | 6 |
| Vikas Goyal | 1 | 5 |
| Faheem Hasnain | 1 | 5 |
| Raj Parekh | 1 | 5 |
| HEIDI HENSON | 1 | 5 |
| James Young | 1 | 4 |
| Henry Skinner | 1 | 4 |
| Andrew Myers | 1 | 4 |
| YI LIU | 1 | 4 |
| Markus Goebel | 1 | 4 |
| CHRISTOPHER C DEWEY | 1 | 4 |
| Mary T. Szela | 1 | 4 |
| PINGDA REN | 1 | 3 |
| James Chomas | 1 | 3 |
| Mats J. Wahlstrom | 1 | 3 |
| Norman R. Weldon | 1 | 3 |
| ANTONIO GUALBERTO | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.